Further, we used the UALCAN to analyze the relationship between IGF2BP3 expression and multiple clinicopathological characteristics of 178 PAAD samples and 4 normal samples in TCGA. This evidence concerns the gene IGF2BP3 and pancreatic adenocarcinoma.